Comments of the Healthcare Supply Chain Association (HSCA) on Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2020
On behalf of the Healthcare Supply Chain Association (HSCA), we appreciate the opportunity to provide comments on the U.S. Drug Enforcement Administration’s (DEA or Agency) proposed aggregate production quotas for Schedule I and II controlled substances. HSCA supports DEA’s efforts to support interagency collaboration around controlling opioid diversion. We are concerned, however, that absent differentiation of injectable opioids from solid dosage form for purposes of the rule, these changes to aggregate production quotas could lead to injectable narcotic shortages that threaten patient care.
Click here for the full comments.
HSCA Applauds House Committee on Energy and Commerce for Commitment to Supporting Quality and Protecting Patients from Counterfeit Medical Products
Washington, DC (March 11, 2020) – Healthcare Supply Chain Association (HSCA)...
HSCA Submits Comments to ANSI on Healthcare Supply Chain Data Standards to Help Improve Accuracy, Efficiency, and Patient Safety
Washington, DC (November 26, 2019) – The Healthcare Supply Chain Association...
Comments of the Healthcare Supply Chain Association to FDA on Identifying the Root Causes of Drug Shortages and Finding Enduring Solutions
On behalf of the Healthcare Supply Chain Association (HSCA), we appreciate the...